Head-To-Head Survey: SHINECO (NASDAQ:SISI) versus Nuvilex (NASDAQ:PMCB)

Profitability

This table compares Nuvilex and SHINECO’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	4.60%	3.76%
SHINECO	-380.55%	-79.89%	-33.01%

Risk and Volatility

Nuvilex has a beta of -0.24, meaning that its share price is 124% less volatile than the S&P 500. Comparatively, SHINECO has a beta of -0.8, meaning that its share price is 180% less volatile than the S&P 500.

Insider & Institutional Ownership

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 4.1% of SHINECO shares are owned by institutional investors. 10.2% of Nuvilex shares are owned by insiders. Comparatively, 0.0% of SHINECO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Nuvilex and SHINECO”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66 million	$2.59	0.40
SHINECO	$9.80 million	0.25	-$22.45 million	N/A	N/A

Nuvilex has higher earnings, but lower revenue than SHINECO.

Summary

Nuvilex beats SHINECO on 7 of the 8 factors compared between the two stocks.

About Nuvilex

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

About SHINECO

Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.